Orexigen Therapeutics Newswire

Orexigen Therapeutics Newswire

Comprehensive Real-Time News Feed for Orexigen Therapeutics.

Results 1 - 20 of 112 in Orexigen Therapeutics

  1. -$2.40 Earnings Per Share Expected for Orexigen Therapeutics, Inc. (OREX) This QuarterRead the original story w/Photo

    Tuesday May 16 | Daily Political

    Wall Street brokerages forecast that Orexigen Therapeutics, Inc. will post earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Orexigen Therapeutics' earnings.

    Comment?

  2. Orexigen Therapeutics, Inc. (OREX) Announces Quarterly Earnings...Read the original story w/Photo

    Wednesday May 10 | AmericanBankingNews.com

    Orexigen Therapeutics, Inc. announced its earnings results on Tuesday. The biopharmaceutical company reported earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of by $2.07.

    Comment?

  3. Orexigen Therapeutics (OREX) Earning Somewhat Favorable Media Coverage, Analysis ShowsRead the original story w/Photo

    Wednesday May 10 | Daily Political

    News headlines about Orexigen Therapeutics have been trending somewhat positive this week, according to Alpha One Sentiment Analysis. The research firm, a division of Accern, identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time.

    Comment?

  4. Short Interest in Orexigen Therapeutics, Inc. (OREX) Decreases By 7.8%Read the original story w/Photo

    Friday May 5 | IntersportsWire

    Orexigen Therapeutics, Inc. was the recipient of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 2,989,333 shares, a decrease of 7.8% from the February 28th total of 3,243,659 shares.

    Comment?

  5. Orexigen Therapeutics (OREX) Earns Daily Media Sentiment Score of -0.11Read the original story w/Photo

    Wednesday May 3 | AmericanBankingNews.com

    News stories about Orexigen Therapeutics have been trending somewhat negative recently, according to AlphaOne. The research firm, a service of Accern, scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time.

    Comment?

  6. Exclusive: Orexigen Therapeutics Execs Talk Contrave And The Stock's Roller-Coaster RideRead the original story w/Photo

    Tuesday May 2 | Benzinga

    Meet Orexigen Therapeutics, Inc. , a micro-cap biopharmaceutical company delivering one of the strongest stock market performances of 2017 so far. After losing almost 90 percent of its value over 2016, shares have recuperated more than 80 percent this year.

    Comment?

  7. BRIEF-Navamedic signs deal with Orexigen Therapeutics for Nordic launch of MysimbaRead the original story w/Photo

    Tuesday May 2 | Reuters

    * HAS ENTERED INTO A FIVE-YEAR AGREEMENT WITH OREXIGEN THERAPEUTICS IRELAND, LTD., FOR NORDIC MARKETING AND DISTRIBUTION OF MYSIMBA , A PRESCRIPTION PHARMACEUTICAL. * NAVAMEDIC EXPECTS TO BEGIN MARKETING PRODUCT DURING Q4 2017 FOR AN INITIAL PERIOD ...

    Comment?

  8. Orexigen Announces Commercialization And Distributorship Arrangement...Read the original story

    Monday May 1 | BioSpace

    Orexigen Announces Commercialization And Distributorship Arrangement With Navamedic ASA For Mysimba In Five Nordic Countries /PRNewswire/ -- Orexigen Therapeutics, Inc. today announced that its wholly owned subsidiary, Orexigen Therapeutics Ireland Ltd., and Navamedic AB, an affiliate of Navamedic ASA , have executed a distributorship agreement covering for MysimbaA . Navamedic ASA manufactures and markets pharmaceutical products and medical technology to patients, hospitals and pharmacies in the Nordic, Benelux and Baltic markets.

    Comment?

  9. -$2.60 EPS Expected for Orexigen Therapeutics, Inc. (OREX) This QuarterRead the original story w/Photo

    Sunday Apr 30 | Daily Political

    Equities research analysts expect Orexigen Therapeutics, Inc. to post earnings of per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Orexigen Therapeutics' earnings.

    Comment?

  10. Somewhat Favorable News Coverage Extremely Likely to Affect Orexigen Therapeutics (OREX) Share PriceRead the original story w/Photo

    Thursday Apr 27 | IntersportsWire

    News headlines about Orexigen Therapeutics have trended somewhat positive on Thursday, AlphaOne Sentiment reports. AlphaOne, a service of Accern, ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time.

    Comment?

  11. Brokerages Expect Orexigen Therapeutics, Inc. (OREX) to Announce -$2.60 Earnings Per ShareRead the original story w/Photo

    Tuesday Apr 25 | AmericanBankingNews.com

    Wall Street analysts expect that Orexigen Therapeutics, Inc. will post earnings per share of for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Orexigen Therapeutics' earnings.

    Comment?

  12. Orexigen Announces New Drug Submission For Contrave In CanadaRead the original story

    Monday Apr 24 | BioSpace

    /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company helping to improve the health and lives of patients struggling with weight loss, today announced that Health Canada has completed its screening phase and accepted ...

    Comment?

  13. Research Reports Initiation on Drug Makers Stocks -- Depomed, Pernix...Read the original story w/Photo

    Apr 4, 2017 | PR Newswire

    Today's research on Stock-Callers.com is focused on the Drug Manufacturers space, which is engaged in the development of prescription and over-the-counter products that are used to prevent or treat illnesses in humans or animals. Four equities have been lined up for review this morning, and they are: Depomed Inc. , Pernix Therapeutics Holdings Inc. , Orexigen Therapeutics Inc. , and United Therapeutics Corp. .

    Comment?

  14. BRIEF-Orexigen Therapeutics announces new drug submission for Contrave in CanadaRead the original story w/Photo

    Tuesday Apr 25 | Reuters

    * Orexigen Therapeutics - if approved, Valeant will market and distribute Contrave in Canada as part of its distributorship agreement with Orexigen Source text for Eikon: Further company coverage: SYDNEY, April 25 Copper reversed early losses in Asia ...

    Comment?

  15. Orexigen Therapeutics, Inc. (OREX) Investor Investigation over Potential WrongdoingRead the original story w/Photo

    Friday Apr 21 | SBWire

    An investigation was announced for investors in shares of Orexigen Therapeutics, Inc. over potential breaches of fiduciary duties by certain directors at Orexigen Therapeutics, Inc. Investors who purchased shares of Orexigen Therapeutics, Inc. have certain options and should contact the Shareholders Foundation at [email protected] or call 858-779-1554. The investigation by a law firm concerns whether certain Orexigen Therapeutics directors breached their fiduciary duties.

    Comment?

  16. Orexigen Therapeutics (OREX) Getting Somewhat Negative Media Coverage, Report FindsRead the original story w/Photo

    Apr 20, 2017 | The Breeze

    News stories about Orexigen Therapeutics have trended somewhat negative recently, according to Alpha One Sentiment Analysis. Alpha One, a subsidiary of Accern, identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real-time.

    Comment?

  17. Orexigen Therapeutics (OREX) Receiving Somewhat Favorable Media Coverage, Analysis ShowsRead the original story w/Photo

    Apr 13, 2017 | AmericanBankingNews.com

    News stories about Orexigen Therapeutics have trended somewhat positive recently, AlphaOne Sentiment Analysis reports. The research group, a service of Accern, rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time.

    Comment?

  18. Orexigen Therapeutics, Inc. (OREX) Sees Large Decrease in Short InterestRead the original story w/Photo

    Apr 12, 2017 | The Breeze

    Orexigen Therapeutics, Inc. saw a large decline in short interest in March. As of March 15th, there was short interest totalling 2,989,333 shares, a decline of 7.8% from the February 28th total of 3,243,659 shares.

    Comment?

  19. Orexigen Therapeutics, Inc. (OREX) Short Interest UpdateRead the original story w/Photo

    Apr 8, 2017 | IntersportsWire

    Orexigen Therapeutics, Inc. was the recipient of a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 2,989,333 shares, a decrease of 7.8% from the February 28th total of 3,243,659 shares.

    Comment?

  20. Orexigen Therapeutics (OREX) Getting Somewhat Negative Press Coverage, Study ShowsRead the original story w/Photo

    Apr 5, 2017 | The Breeze

    News headlines about Orexigen Therapeutics have been trending somewhat negative this week, according to Alpha One Sentiment Analysis. The research firm, a subsidiary of Accern, ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time.

    Comment?